Compare Incyte Corporation (INCY) vs Vanguard Growth Index Fund ETF (VUG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Vanguard Growth Index Fund ETF — how do they compare? Incyte Corporation trades at $118.08 (market cap $23.11B), while Vanguard Growth Index Fund ETF trades at $86.22. The key difference: Incyte Corporation is trading nearer its 52-week high, Vanguard Growth Index Fund ETF nearer its low. Which is the better fit depends on your goals.
| INCY | VUG | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Sector/Thematic |
52-Week High | $118.52 | $90.29 |
52-Week Low | $67.38 | $70.00 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
VUG trades at $85.32, up 0.06% with a bearish technical signal from moving averages. The ETF's low expense ratio of 0.03% and strong historical returns, including a 411% total return over the past decade per The Motley Fool (2026-07-12), highlight its cost efficiency. Recent news emphasizes its growth focus and tech-heavy holdings, with a stock split executed on 21 April 2026. Support levels are clustered around $84-$85, indicating potential near-term stability.
Outlook remains positive for long-term investors due to VUG's low-cost structure and exposure to high-growth U.S. large-cap stocks. Risks include high concentration in technology sectors and market volatility. Analyst sentiment is generally favorable, supporting a buy-and-hold strategy for wealth accumulation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Vanguard Growth Index Fund ETF
VUG is an index-based ETF that tracks the CRSP US Large Cap Growth Index, providing concentrated exposure to the largest and fastest-growing companies in the United States. It focuses on stocks with high growth potential across tech, communication, and consumer sectors, serving as a low-cost, high-conviction core holding for long-term capital appreciation.
Read more on VUG →
